229 related articles for article (PubMed ID: 25524010)
21. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
22. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
23. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
24. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Nair JS; de Stanchina E; Schwartz GK
Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
[TBL] [Abstract][Full Text] [Related]
25. Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
Némati F; de Montrion C; Lang G; Kraus-Berthier L; Carita G; Sastre-Garau X; Berniard A; Vallerand D; Geneste O; de Plater L; Pierré A; Lockhart B; Desjardins L; Piperno-Neumann S; Depil S; Decaudin D
PLoS One; 2014; 9(1):e80836. PubMed ID: 24454684
[TBL] [Abstract][Full Text] [Related]
26. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
27. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Sun J; Tan CJ; Dai Z
Expert Opin Investig Drugs; 2009 Nov; 18(11):1595-604. PubMed ID: 19780708
[TBL] [Abstract][Full Text] [Related]
29. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
[TBL] [Abstract][Full Text] [Related]
30. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
31. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
[TBL] [Abstract][Full Text] [Related]
32. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy.
Talarico C; D'Antona L; Scumaci D; Barone A; Gigliotti F; Fiumara CV; Dattilo V; Gallo E; Visca P; Ortuso F; Abbruzzese C; Botta L; Schenone S; Cuda G; Alcaro S; Bianco C; Lavia P; Paggi MG; Perrotti N; Amato R
Oncotarget; 2015 Nov; 6(35):37511-25. PubMed ID: 26462020
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
[TBL] [Abstract][Full Text] [Related]
34. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
[TBL] [Abstract][Full Text] [Related]
35. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
36. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter.
Wu CH; Ho YS; Tsai CY; Wang YJ; Tseng H; Wei PL; Lee CH; Liu RS; Lin SY
Int J Cancer; 2009 May; 124(9):2210-9. PubMed ID: 19123483
[TBL] [Abstract][Full Text] [Related]
38. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
39. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
40. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
